GlassScriptPhysician profile
Khin Khin Oo
NPI 1588638043
$8,509.50
in general payments reported to CMS, 2019-2025
23 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $787 · 2021: $1,428 · 2022: $1,043 · 2023: $1,545 · 2024: $1,408 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,199 · Travel and Lodging: $15.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.14 |
| Travel and Lodging | $15.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,713.34 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,545.68 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $626.13 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $605.86 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $559.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $331.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.86 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $249.34 | 2023 | Arexvy |
| Pfizer INC. | $227.35 | 2019-2025 | |
| Amarin Pharma, INC. | $159.17 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.17 | 2021 | |
| Phathom Pharmaceuticals, INC. | $149.98 | 2025 | Voquezna |
| Radius Health, INC. | $144.25 | 2019-2024 | Tymlos |
| Gilead Sciences, INC. | $142.21 | 2023 | Epclusa |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $114.07 | 2022 | |
| Merck Sharp & Dohme LLC | $109.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $102.26 | 2019-2025 | |
| Allergan, INC. | $49.56 | 2019-2020 | |
| Cepheid | $45.66 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $30.08 | 2021 | |
| Exact Sciences Corporation | $22.93 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.12 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khin Oo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.